cagrilintide retatrutide GLP-3 (12mg vials) cagrilintide doses Buy (Cagri) |

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema

These injections, part of a broader category of medical weight loss solutions, are scientifically formulated to reduce body weight when combined with a healthy lifestyle

Product Name: REGENO Cartalax + TB-500 + BPC-157 Strength: 30mg Total Peptide Content Blend Composition: Cartalax 10mg TB-500 10mg BPC-157 10mg Chemical Name: Multi-Peptide Research Blend (Cartalax + TB-500 + BPC-157) Appearance: White to Off-White Lyophilized Powder Classification: Multi-Peptide Research Compound Purity: Verified by analytical testing prior to release Analytical Methods: HPLC, Mass Spectrometry (MS) Research areas commonly associated with this compound include: Composite Peptide Research Tissue Organization Studies Extracellular Matrix Research Cartilage Signaling Studies Cellular Migration Research Store lyophilized material refrigerated at 28C for routine storage

Do not use that vial

Reconstitution done right: a mistake at the BAC water step changes your dose by an order of magnitude

Disposable pens often have lower upfront costs but require constant repurchase